The Next-generation Sequencing Services Market is expected to grow at a CAGR of 20.4% from 2021 to 2028 to reach $14.1 billion by 2028. The growth of this market is mainly attributed to the reducing cost of NGS procedures, the development and approval of new targeted therapies, rising prevalence of cancer, partnerships between NGS service providers and pharmaceutical companies, high cost of sequencing infrastructure, and technological advancements in NGS. In addition, advancements in sequencing data analytics and the increasing applications of NGS in cancer and agri-genomics research are expected to offer significant growth opportunities for NGS service providers.
However, the availability of alternative technologies, lack of skilled professionals for sample preparation and analysis, and actionable mutations for precision medicine may restrain the growth of the NGS services market. Moreover, regulatory & standardization concerns in diagnostic testing and the ethical issues & costs related to non-invasive prenatal genetic testing are major challenges for the growth of this market.
Impact of COVID-19 Pandemic on the NGS Services Market
The COVID-19 virus SARS-CoV-2 was quickly identified due to the power of next-generation sequencing. Advances in NGS allowed the sequencing of SARS-CoV-2 to be completed within hours. Information of the virus's genome sequence enabled the rapid development of diagnostic assays and other response tools. The monitoring of the disease's transmission, activity, and evolution was aided by continued genome sequencing.
Currently, the COVID-19 pandemic is still ongoing, with new viral variations emerging around the globe. The pandemic has highlighted the need to integrate genome sequencing into the practices of the global health community. Many countries are focused on the genomic sequencing of the COVID-19 virus. The sequencing data is important for studying and understanding viral mutations. The mutations occurring in the virus genome must be tracked, as they may reduce the efficacy of the current safety protocols, tests, vaccines, and clinical care. Hence, for the authorities to plan an accurate public health action, genome sequencing of the virus is very important. For instance, in February 2020, the Netherlands sequenced its first positive samples and initiated its public health action by analyzing genomic data. According to a McKinsey report, the U.S. sequenced around 200,000 of its COVID-19 cases, while the U.K. sequenced 350,000 cases.
Furthermore, to enhance the genomic sequencing capabilities, the U.S. government allocated USD 1.7 billion to the CDC from the American Rescue Plan of 2021. Efforts are also being taken to sequence and analyze SARS-CoV-2 genomes by expanding the capacities of public health laboratories and establishing partnerships with academia and the private sector. The CDC has collaborated with several labs such as Laboratory Corporation of America Holdings (U.S.) and Quest Diagnostics (U.S.), as well as sequencing equipment manufacturers such as Illumina, Inc. (U.S.) to increase the country's sequencing capacity.
In August 2021, the Indian Ministry of Science and Technology announced a collaborative approach under the BRICS- multilateral research and development project. In this collaborative research, scientists from India, China, Russia, and Brazil will carry out the whole genome sequencing of SARS-CoV-2 and work on the epidemiology and mathematical modeling of the COVID-19 pandemic.
Furthermore, many NGS-based diagnostic tests were also developed. For instance, in June 2020, COVIDSeq, an NGS-based test from Illumina Inc. (U.S.), received emergency use authorization from the U.S. FDA for the qualitative detection and diagnosis of COVID-19. Similarly, NGS-based tests such as LamPORE by Oxford Nanopore Technologies Limited (U.K.) and SwabSeq by Octant, Inc. (U.S.) have been developed to diagnose COVID-19. NGS diagnostics are currently utilized in a relatively limited way, but they may become more frequently utilized in the future if they receive regulatory approvals from many countries and are demonstrated to be more effective than other testing methods.
There is a huge scope for the growth of the NGS services market as more countries implement sequencing programs to better understand emerging pathogens and their interactions with humans and animals.
Click here to: Get Free Sample Pages of this Report
Key Findings in the Global Next-generation Sequencing Services Market Study
The exome sequencing services segment is expected to grow at the highest CAGR during the forecast period
Based on type, the global NGS services market is segmented into targeted sequencing services, whole-genome sequencing services, RNA sequencing services, exome sequencing services, de novo sequencing services, ChIP sequencing services, methyl sequencing services, and other NGS services. The exome sequencing services segment is expected to grow at the highest CAGR during the forecast period. The advantages of exome sequencing, such as being a comparatively cost-effective alternative to whole-genome sequencing while achieving comprehensive coverage of coding regions, drive the growth of this market. Exomes are protein-coding genes estimated to encompass approximately 1% of the whole genome yet contain approximately 85% of disease-causing mutations.
The single-molecule real-time sequencing segment is expected to grow at the highest CAGR during the forecast period
Based on technology, the global NGS services market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing (IOS), single-molecule real-time sequencing (SMRT), nanopore sequencing, and other NGS technologies. The single-molecule real-time sequencing segment is expected to grow at the highest CAGR during the forecast period. The ability of this technology to provide highly accurate long reads with single-molecule resolutions drives the growth of this segment. Single-molecule real-time (SMRT) sequencing technology is based on directly observing a single strand of DNA synthesis. SMRT sequencing not only reports which nucleotides the polymerase incorporates but also records the polymerase kinetics.
The biomarker discovery segment is expected to grow at the highest CAGR during the forecast period
Based on application, the global NGS services market is segmented into biomarker discovery, diagnostics, drug discovery, agriculture & animal research, and other applications. The biomarker discovery segment is expected to grow at the highest CAGR during the forecast period. The advantages of NGS in discovering biomarkers, such as its high sensitivity and throughput and the rising importance of biomarker discovery in predicting and monitoring diseases, such as cancer and other chronic diseases, support the growth of this segment. Biomarkers are valuable for early diagnosis, prediction, and monitoring of the therapeutic efficacy of medicine and are particularly important in personalized medicine.
In 2021, the hospitals & clinics segment is estimated to account for the largest share of the global NGS services market
Based on end user, the global NGS services market is segmented into hospitals & clinics, pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2021, the hospitals & clinics segment is estimated to account for the largest share of the global NGS services market. The large share of this segment is attributed to factors such as high capital requirements for building in-house NGS capabilities in hospitals & clinics, the rising prevalence of cancer and other chronic diseases, the growing demand for advanced medical treatments, and the rising number of biomarker-based therapies.
In 2021, North America is estimated to account for the largest share of the global NGS services market
Based on region, the NGS services market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In 2021, North America is estimated to account for the largest share of the global NGS services market. The large share of North America in the NGS services market is primarily attributed to the presence of leading NGS service providers in the region, favorable government initiatives for genomics research, growing applications of NGS-based research, declining cost of sequencing coupled with the rising awareness of NGS, increasing research investments by pharmaceutical and biopharmaceutical companies, increasing cancer prevalence, and favorable reimbursement scenario in the region.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments that market participants adopted over the past four years. The key players profiled in the global next-generation sequencing services market report include Illumina, Inc. (U.S.), Qiagen N.V. (Netherland), PerkinElmer, Inc. (U.S.), Eurofins Scientific S.E. (Luxembourg), Macrogen, Inc. (South Korea), LGC Limited (U.K.), GENEWIZ, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), SciGenom Labs Pvt. Ltd (India), MedGenome Inc. (U.S.), DNA Link, Inc. (South Korea), Otogenetics Corporation (U.S.), Novogene Co., Ltd. (China), CD Genomics (U.S.), Foundation Medicine, Inc. (U.S), and SeqLL, Inc. (U.S.).
Scope of the Report
NGS Services Market, by Type
NGS Services Market, by Technology
NGS Services Market, by Application
NGS Services Market, by End User
NGS Services Market, by Geography
Key questions answered in the report:
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for This Study
2.5. Limitations for The Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Plummeting Costs of Sequencing Procedures
4.2.2. Development and Approval of New Targeted Therapies
4.2.3. Rising Prevalence of Cancer
4.2.4. Partnerships Between NGS Service Providers and Pharmaceutical Companies
4.2.5. High Cost of Sequencing Infrastructure
4.2.6. Technological Advancements in NGS
4.3. Restraints
4.3.1. Availability of Alternative Technologies
4.3.2. Lack of Skilled Professionals for Sample Preparation and Analysis
4.3.3. Low Chances of Positive Actionable Mutations for Precision Medicine
4.4. Opportunities
4.4.1. Increasing Applications in Cancer and Agri-Genomics Research
4.4.2. Advancements in Sequencing Data Analytics
4.5. Challenges
4.5.1. Regulatory & Standardization Concerns in Diagnostic Testing
4.5.2. Installation of In-House NGS Facilities in Large Hospitals and Research Institutes
4.5.3. Ethical Issues & Costs Related to Non-Invasive Prenatal Genetic Testing
4.6. The Impact of Covid-19 on The Global NGS Services Market
5. Global Next-Generation Sequencing Services Market, by Type
5.1. Introduction
5.2. Targeted Sequencing Services
5.3. RNA Sequencing Services
5.4. De Novo Sequencing Services
5.5. Exome Sequencing Services
5.6. Chip Sequencing Services
5.7. Methyl Sequencing Services
5.8. Whole-Genome Sequencing Services
5.9. Other NGS Services
6. Global Next-Generation Sequencing Services Market, by Technology
6.1. Introduction
6.2. Sequencing by Synthesis (SBS)
6.3. Ion Semiconductor Sequencing (IOS)
6.4. Single-Molecule Real-Time (SMRT) Sequencing
6.5. Nanopore Sequencing
6.6. Other NGS Technologies
7. Global Next-Generation Sequencing Services Market, by Application
7.1. Introduction
7.2. Diagnostics
7.3. Drug Discovery
7.4. Biomarker Discovery
7.5. Agriculture & Animal Research
7.6. Other Applications
8. Global Next-Generation Sequencing Services Market, by End User
8.1. Introduction
8.2. Hospitals & Clinics
8.3. Pharmaceutical & Biotechnology Companies
8.4. Academics & Research Institutes
8.5. Other End Users
9. Global NGS Services Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2020)
10.4.1. Eurofins Scientific S.E.
10.4.2. Illumina, Inc.
10.4.3. Perkinelmer, Inc.
10.4.4. GENEWIZ, Inc.
10.4.5. Foundation Medicine, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
11. Company Profiles
11.1. Illumina, Inc.
11.1.1. Business Overview
11.1.2. Financial Overview
11.1.3. Service Portfolio
11.1.4. Strategic Developments
11.2. QIAGEN N.V.
11.2.1. Business Overview
11.2.2. Financial Overview
11.2.3. Service Portfolio
11.3. PerkinElmer, Inc.
11.3.1. Business Overview
11.3.2. Financial Overview
11.3.3. Service Portfolio
11.4. Eurofins Scientific S.E.
11.4.1. Business Overview
11.4.2. Financial Overview
11.4.3. Service Portfolio
11.4.4. Strategic Developments
11.5. Macrogen, Inc.
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Service Portfolio
11.5.4. Strategic Developments
11.6. LGC Limited
11.6.1. Business Overview
11.6.2. Financial Overview
11.6.3. Service Portfolio
11.6.4. Strategic Developments
11.7. GENEWIZ, Inc.
11.7.1. Business Overview
11.7.2. Financial Overview
11.7.3. Service Portfolio
11.7.4. Strategic Developments
11.8. Beijing Genomics Institute (BGI)
11.8.1. Business Overview
11.8.2. Service Portfolio
11.8.3. Strategic Developments
11.9. Scigenom Labs Pvt., Ltd.
11.9.1. Business Overview
11.9.2. Service Portfolio
11.10. Medgenome Inc.
11.10.1. Business Overview
11.10.2. Service Portfolio
11.10.3. Strategic Developments
11.11. DNA Link, Inc.
11.11.1. Business Overview
11.11.2. Service Portfolio
11.12. Otogenetics Corporation
11.12.1. Business Overview
11.12.2. Service Portfolio
11.13. Novogene Co., Ltd.
11.13.1. Business Overview
11.13.2. Service Portfolio
11.13.3. Strategic Developments
11.14. CD Genomics
11.14.1. Business Overview
11.14.2. Service Portfolio
11.14.3. Strategic Developments
11.15. SeqLL Inc.
11.15.1. Business Overview
11.15.2. Financial Overview
11.15.3. Service Portfolio
11.16. Foundation Medicine, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
11.16.1. Business Overview
11.16.2. Financial Overview
11.16.3. Service Portfolio
11.16.4. Strategic Developments
12. Appendix
12.1. Questionnaire
12.2. Available Customization
List of Tables
Table 1 NGS Services Market Drivers: Impact Analysis (2021–2028)
Table 2 Currently Available Targeted Therapies and Corresponding Biomarkers
Table 3 Estimated Number of New Cancer Cases, by Type (2020)
Table 4 NGS Services Market Restraints: Impact Analysis (2021–2028)
Table 5 Global NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 6 Global Targeted Sequencing Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 7 Global RNA Sequencing Services Market Size, by Country/Region, 2019–2028
(USD Million)
Table 8 Global De Novo Sequencing Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 9 Global Exome Sequencing Services Market Size, by Country/Region, 2019–2028
(USD Million)
Table 10 Global Chip Sequencing Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 11 Global Methyl Sequencing Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 12 Global Whole-Genome Sequencing Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 13 Global Other NGS Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 14 Global NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 15 Global Sbs-based NGS Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 16 Global Ios-based NGS Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 17 Global Smart Technology-based NGS Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 18 Global Nanopore Technology-based NGS Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 19 Global Other Technologies-based NGS Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 20 Global NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 21 Global NGS Services Market Size for Diagnostics, by Country/Region, 2019–2028 (USD Million)
Table 22 Global NGS Services Market Size for Drug Discovery, by Country/Region, 2019–2028 (USD Million)
Table 23 Tumor Markers in Different Cancer Types
Table 24 Global NGS Services Market Size for Biomarker Discovery, by Country/Region, 2019–2028 (USD Million)
Table 25 Global NGS Services Market Size for Agriculture & Animal Research, by Country/Region, 2019–2028 (USD Million)
Table 26 Global NGS Services Market Size for Other Applications, by Country/Region, 2019–2028 (USD Million)
Table 27 Global NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 28 Global NGS Services Market Size for Hospitals & Clinics, by Country/Region, 2019–2028 (USD Million)
Table 29 Global NGS Services Market Size for Pharmaceutical & Biotechnology Companies, by Country/Region, 2019–2028 (USD Million)
Table 30 Global NGS Services Market Size for Academic & Research Institutes, by Country/Region, 2019–2028 (USD Million)
Table 31 Global NGS Services Market Size for Other End Users, by Country/Region, 2019–2028 (USD Million)
Table 32 Global NGS Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 33 North America: NGS Services Market Size, by Country, 2019–2028 (USD Million)
Table 34 North America: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 35 North America: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 36 North America: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 37 North America: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 38 U.S.: Key Macroindicators
Table 39 U.S.: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 40 U.S.: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 41 U.S.: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 42 U.S.: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 43 Canada: Key Macroindicators
Table 44 Canada: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 45 Canada: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 46 Canada: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 47 Canada: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 48 Europe: NGS Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 49 Europe: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 50 Europe: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 51 Europe: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 52 Europe: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 53 Germany: Key Macroindicators
Table 54 Germany: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 55 Germany: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 56 Germany: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 57 Germany: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 58 France: Key Macroindicators
Table 59 France: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 60 France: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 61 France: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 62 France: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 63 U.K.: Key Macroindicators
Table 64 U.K.: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 65 U.K.: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 66 U.K.: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 67 U.K.: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 68 Italy: Key Macroindicators
Table 69 U.K.: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 70 Italy: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 71 Italy: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 72 Italy: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 73 Spain: Key Macroindicators
Table 74 Spain: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 75 Spain: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 76 Spain: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 77 Spain: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 78 Estimated Number of New Cancer Cases From 2020 To 2030
Table 79 Roe: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 80 Roe: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 81 Roe: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 82 Roe: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 83 Asia-Pacific: NGS Services Market Size, by Country/Region, 2019–2028 (USD Million)
Table 84 Asia-Pacific: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 85 Asia-Pacific: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 86 Asia-Pacific: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 87 Asia-Pacific: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 88 Japan: Key Macroindicators
Table 89 Japan: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 90 Japan: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 91 Japan: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 92 Japan: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 93 China: Key Macroindicators
Table 94 China: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 95 China: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 96 China: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 97 China: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 98 India: Key Macroindicators
Table 99 India: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 100 India: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 101 India: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 102 India: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 103 Estimated Number of New Cancer Cases From 2020 To 2030
Table 104 Roapac: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 105 Roapac: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 106 Roapac: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 107 Roapac: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 108 Latin America: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 109 Latin America: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 110 Latin America: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 111 Latin America: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 112 Middle East & Africa: NGS Services Market Size, by Type, 2019–2028 (USD Million)
Table 113 Middle East & Africa: NGS Services Market Size, by Technology, 2019–2028 (USD Million)
Table 114 Middle East & Africa: NGS Services Market Size, by Application, 2019–2028 (USD Million)
Table 115 Middle East & Africa: NGS Services Market Size, by End User, 2019–2028 (USD Million)
Table 116 Recent Developments, by Company, 2018—2021
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Size Estimation
Figure 7 Global Next-generation Sequencing Services Market Size, by Application, 2021 Vs. 2028 (USD Million)
Figure 8 Global Next-generation Sequencing Services Market Size, by Type, 2021 Vs. 2028 (USD Million)
Figure 9 Global Next-generation Sequencing Services Market Size, by Technology, 2021 Vs. 2028 (USD Million)
Figure 10 Global Next-generation Sequencing Services Market Size, by End User, 2021 Vs. 2028 (USD Million)
Figure 11 Next-generation Sequencing Services Market, by Geography
Figure 12 Market Dynamics
Figure 13 Cost of Genome Sequencing: 2010–2020
Figure 14 Global NGS Services Market Size, by Type, 2021–2028 (USD Million)
Figure 15 Number of Manuscripts Featuring RNA Sequencing Per Year on Pubmed
Figure 16 Global NGS Services Market Size, by Technology, 2021–2028 (USD Million)
Figure 17 Global NGS Services Market Size, by Application, 2021–2028 (USD Million)
Figure 18 New Molecular Entity (NME) Approvals Per Year
Figure 19 Global NGS Services Market Size, by End User, 2021–2028 (USD Million)
Figure 20 Global Biopharmaceutical R&D Spending, 2014–2020 (USD Billion)
Figure 21 Global NGS Services Market Size, by Geography, 2021–2028 (USD Million)
Figure 22 North America: NGS Services Market Snapshot
Figure 23 Pharmaceutical R&D Expenditure in the U.S.
Figure 24 Pharmaceutical Industry Research and Development in Europe (2019)
Figure 25 Europe: NGS Services Market Snapshot
Figure 26 Number of Biotechnology Firms in Italy, 2008-2019
Figure 27 R&D Spending by Pharmaceutical Industry in Spain, 2015-2019 (USD Million)
Figure 28 Pharmaceutical R&D Spending in Roe (2019)
Figure 29 Asia-Pacific: NGS Services Market Snapshot
Figure 30 Key Growth Strategies Adopted by Leading Players, 2018—2021
Figure 31 NGS Services: Competitive Benchmarking (Based on Service Type)
Figure 32 NGS Services: Competitive Benchmarking (Based on Geography)
Figure 33 Market Share Analysis: NGS Services Industry, 2020
Figure 34 Illumina, Inc.: Financial Overview, 2020
Figure 35 Qiagen N.V.: Financial Overview, 2020
Figure 36 Perkinelmer, Inc.: Financial Overview, 2020
Figure 37 Eurofins Scientific S.E.: Financial Overview, 2020
Figure 38 Macrogen, Inc.: Financial Overview, 2020
Figure 39 LGC Limited: Financial Overview, 2020
Figure 40 Brooks Automation, Inc.: Financial Overview, 2020
Figure 41 SeqLL Inc.: Financial Overview, 2020
Figure 42 F. Hoffmann-La Roche AG.: Financial Overview, 2020
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Apr-2023
Published Date: Feb-2023
Published Date: Jan-2023
Published Date: Oct-2022
